摘要
慢性肾脏病(chronic kidney disease,CKD)是一种长期性进展性疾病,是以肾功能丢失逐渐加重为特征的一种疾病,甚至会导致终末期肾脏疾病,需要肾移植或者肾透析。贫血是CKD患者的常见并发症,且随肾功能下降贫血发生率不断上升。红细胞生成刺激剂(erythropoiesis stimulating agents,ESAs)是目前治疗肾性贫血的主导药物,然而,心血管安全风险限制了ESAs的应用。所以,近几年开始探索新型的红细胞生成刺激剂制剂,一种新型口服的低氧诱导因子脯氨酰羟化酶(hypoxia-inducible factor-prolyl hydroxylase,HIF-PHD)抑制剂,日益受到国内外研究人员的关注,然而系统的综述较少。鉴于此,本文将对新型的口服低氧诱导因子脯氨酰羟化酶抑制剂的作用机制及全球研究进展进行综述,重点对目前研发比较成熟进入临床阶段的药物进行综述。
Chronic kidney disease（CKD） is a long-term progressive disease that is characterized by increasing loss of kidney function that can ultimately lead to end-stage renal disease requiring kidney transplant or dialysis. Anemia is a common complication in patients with CKD,with increasing incidence as the disease progresses.Erythropoiesis-stimulating agents（ESAs） are the mainstay of renal anemia management but cardiovascular safety concerns have limited their use. Hypoxia-inducible factor prolyl hydroxylase（HIF-PHD） inhibitors are a new class of oral drugs for the treatment of renal anemia. More and more attention has been paid to the research on HIF-PHD inhibitors at home and abroad but limited systematic reviews are reported. In this paper,the action mechanism of HIF-PHD inhibitors and their research advances are reviewed,with focus on the drugs under clinical investigation.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2017年第22期2701-2705,共5页
Chinese Journal of New Drugs
